Peter focuses on international patent litigation in the fields of pharmaceutical products, biotech inventions and medical devices. He was admitted to the bar in 1998 after law and molecular biology studies at the University of Amsterdam and was one of the founders of Brinkhof.
Within the field, Peter has developed a preference for litigation on pharmaceuticals and more in particular supplementary protection certificates (SPCs); he was among others involved in SPC cases for the monoclonal antibodies cetuximab (Erbitux®) and adalimumab (Humira®). Other areas of interest are licensing/development deals in medical devices and pharmaceuticals, damages recovery proceedings and professional liability. Recent victories were obtained for clients in disputes on clopidogrel/aspirin (Plavix®), dorzolamide/timolol (Cosopt®) and fluticasone/salmeterol (Seretide®) combination patents, as well as docetaxel (Taxotere®) and fexofenadine (Telfast®) patents.
Peter is a member of EPLAW, is Chief Editor of the Kluwer Case Reporter services and contributes to several handbooks in the field. He is also a regular speaker on the topics of pharmaceutical patents and SPCs.